ACADIA PHARMACEUTICALS INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2019-12-31 was $2.21M, a 67.96% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2019-09-30 was $0.00.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2019-06-30 was $2.20M, a 7.02% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2018-12-31 was $1.32M.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $5.51M, a 4.55% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $5.27M, a 9.40% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $4.82M, a 7.25% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $4.49M, a 15.40% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2025-12-31 | $5.51M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $5.27M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $4.82M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $4.49M 10-K · filed 2025-02-27 | |
| 2021-12-31 | $5.31M 10-K · filed 2024-02-28 | |
| 2020-12-31 | $7.16M 10-K · filed 2023-02-28 | |
| 2019-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.41M 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | |
| 2019-06-30 | $2.20M 10-Q · filed 2019-08-01 | |
| 2018-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.68M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | |
| 2018-06-30 | $2.37M 10-Q · filed 2019-08-01 | |
| 2017-12-31 | $4.52M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $3.13M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $1.56M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $664.00K 10-K · filed 2017-02-28 | |
| 2013-12-31 | $358.00K 10-K · filed 2016-02-29 | |
| 2012-12-31 | $123.00K 10-K · filed 2015-02-26 | |
| 2011-12-31 | $109.00K 10-K · filed 2014-02-27 | |
| 2010-12-31 | $65.00K 10-K · filed 2013-03-12 | |
| 2009-12-31 | $193.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |